GlassScriptPhysician profile
Emily A Royce
NPI 1003409491
$614.66
in general payments reported to CMS, 2019-2025
14 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $69.41 | 2025 | |
| Pfizer INC. | $63.76 | 2025 | |
| Dendreon Pharmaceuticals LLC | $63.22 | 2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $60.94 | 2025 | |
| Tolmar, INC. | $53.58 | 2025 | Eligard |
| Abbvie INC. | $46.92 | 2025 | |
| Janssen Biotech, INC. | $42.72 | 2025 | Erleada |
| Endo USA, INC. | $41.45 | 2025 | Xiaflex, Aveed |
| Astellas Pharma US INC | $33.73 | 2025 | Padcev |
| Blue Earth Diagnostics | $33.45 | 2025 | Posluma |
| Telix Pharmaceuticals | $32.47 | 2025 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $27.63 | 2025 | Lynparza |
| Merck Sharp & Dohme LLC | $24.97 | 2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $20.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Royce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.